GLPwatch
Papers (12034)
Page 81 of 201, ranked by citation count.
- Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.
- Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.
- Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14.
- In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
- Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.
- Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
- Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.
- The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
- Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells.
- Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice.
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
- Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma.
- Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
- Combination of ELISA and dried blood spot technique for the quantification of large molecules using exenatide as a model.
- Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.
- Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study.
- Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
- Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Randomized Controlled Trial.
- Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.
- Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide.
- The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.
- Exendin-4 promotes bone formation in diabetic states via HDAC1-Wnt/β-catenin axis.
- Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
- Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy.
- Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.
- A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.
- Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
- Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal.
- Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
- Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
- Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.
- Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
- The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
- Retatrutide showing promise in obesity (and type 2 diabetes).
- Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
- Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir.
- Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
- Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.
- Exendin-4 promotes pancreatic β-cell proliferation via inhibiting the expression of Wnt5a.
- Functional association of the N-terminal residues with the central region in glucagon-related peptides.
- Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
- Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
- Exploring the potential impact of GLP-1 receptor agonists in cancer therapy.
- Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.
- Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence.
- Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration.
- Oral proniosomal amitriptyline and liraglutide for management of diabetic neuropathy: Exceptional control over hyperglycemia and neuropathic pain.
- Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
- Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.
- GLP-1R agonists: recent advances, current gaps, and future challenges.
- Peptide ligations accelerated by N-terminal aspartate and glutamate residues.
- Albiglutide: Is a better hope against diabetes mellitus?
- Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.
- Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles.
- Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats.
- GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
- Cardiovascular outcomes and safety with antidiabetic drugs.